首页> 外文期刊>Stem cells translational medicine. >Generation of Osteosarcomas from a Combination of Rb Silencing and c‐Myc Overexpression in Human Mesenchymal Stem Cells
【24h】

Generation of Osteosarcomas from a Combination of Rb Silencing and c‐Myc Overexpression in Human Mesenchymal Stem Cells

机译:人骨髓间充质干细胞中Rb沉默和c-Myc过表达的结合产生骨肉瘤。

获取原文
           

摘要

Osteosarcoma (OS) was a malignant tumor occurring with unknown etiology that made prevention and early diagnosis difficult. Mesenchymal stem cells (MSCs), which were found in bone marrow, were claimed to be a possible origin of OS but with little direct evidence. We aimed to characterize OS cells transformed from human MSCs (hMSCs) and identify their association with human primary OS cells and patient survival. Genetic modification with p53 or retinoblastoma (Rb) knockdown and c‐Myc or Ras overexpression was applied for hMSC transformation. Transformed cells were assayed for proliferation, differentiation, tumorigenecity, and gene expression profile. Only the combination of Rb knockdown and c‐Myc overexpression successfully transformed hMSCs derived from four individual donors, with increasing cell proliferation, decreasing cell senescence rate, and increasing ability to form colonies and spheres in serum‐free medium. These transformed cells lost the expression of certain surface markers, increased in osteogenic potential, and decreased in adipogenic potential. After injection in immunodeficient mice, these cells formed OS‐like tumors, as evidenced by radiographic analyses and immunohistochemistry of various OS markers. Microarray with cluster analysis revealed that these transformed cells have gene profiles more similar to patient‐derived primary OS cells than their normal MSC counterparts. Most importantly, comparison of OS patient tumor samples revealed that a combination of Rb loss and c‐Myc overexpression correlated with a decrease in patient survival. This study successfully transformed human MSCs to OS‐like cells by Rb knockdown and c‐Myc overexpression that may be a useful platform for further investigation of preventive and target therapy for human OS. S tem C ells T ranslational M edicine 2017;6:512–526
机译:骨肉瘤(OS)是一种病因不明的恶性肿瘤,难以预防和早期诊断。在骨髓中发现的间充质干细胞(MSCs)可能是OS的起源,但缺乏直接证据。我们旨在表征从人类MSC(hMSC)转化而来的OS细胞,并确定它们与人类原代OS细胞和患者生存率的关联。通过p53或视网膜母细胞瘤(Rb)敲除和c-Myc或Ras过表达进行基因修饰可用于hMSC转化。分析转化细胞的增殖,分化,致瘤性和基因表达谱。只有Rb抑制和c-Myc过表达的组合才能成功转化源自四个个体供体的hMSC,从而增加细胞增殖,降低细胞衰老率并增加在无血清培养基中形成菌落和球体的能力。这些转化的细胞失去了某些表面标记的表达,成骨潜能增加,而成脂潜能降低。免疫缺陷小鼠注射后,这些细胞形成了OS样肿瘤,放射学分析和各种OS标记物的免疫组织化学证明了这一点。带有聚类分析的微阵列显示,这些转化细胞的基因谱与患者来源的原代OS细胞相比,与正常的MSC相似。最重要的是,OS患者肿瘤样本的比较显示,Rb丢失和c-Myc过表达的组合与患者存活率降低相关。这项研究通过敲除Rb和c-Myc过表达成功地将人MSC转化为OS样细胞,这可能是进一步研究人OS预防和靶标治疗的有用平台。系统杂志翻译医学杂志,2017年; 6:512–526

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号